Biondvax Pharmaceuticals Ltd., of Nes Ziona, Israel, said it has been awarded NIS4.87 million (US$1.34 million) by the Chief Scientist in the Ministry of Economy for the continued development of its universal influenza vaccine. The grant will be used to promote the company's effort toward a phase III trial with its universal vaccine.